Offerings // Estrella Immunopharma, Inc.

ESLAW offering history

Every offering-related filing in Estrella Immunopharma, Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 250 filings back to Feb 19, 2021.

Last executed offering

Jan 6, 2026

424B5 — priced deal (shares or notes)

Last registration (announced)

Jan 22, 2026

S-1/A — capacity, not a sale

Executed, last 12 months

424B pricings + 8-K 3.02 sales

Registered, last 12 months

S-1/S-3/F-series registrations

Date	Filing		What it means
Feb 13, 2026	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jan 23, 2026	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jan 22, 2026	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Jan 16, 2026	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Jan 6, 2026	424B5 →	EXECUTED	Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)
Jan 6, 2026	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Dec 22, 2025	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Jun 3, 2025	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Dec 19, 2024	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Dec 17, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Dec 12, 2024	S-3 →	REGISTERED	S-3 registration — capacity to sell shares, not a sale yet
Dec 9, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Nov 27, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Nov 18, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Oct 2, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Aug 21, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Aug 6, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jul 2, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
May 15, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Mar 11, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Mar 7, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Feb 16, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Feb 12, 2024	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Dec 28, 2023	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Dec 28, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Dec 18, 2023	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Nov 13, 2023	S-1/A →	REGISTERED	S-1/A registration — capacity to sell shares, not a sale yet
Oct 11, 2023	S-1 →	REGISTERED	S-1 registration — capacity to sell shares, not a sale yet
Oct 5, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Sep 20, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Sep 18, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Aug 18, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jul 26, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jul 21, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jul 19, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Jul 11, 2023	424B3 →	UPDATE	Prospectus update — often a resale registration, not necessarily new capital
Jul 11, 2023	EFFECT →	EFFECTIVE	SEC declared a registration effective — selling can begin
Jun 9, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
May 19, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)
Apr 13, 2023	8-K →	EXECUTED	Unregistered share sale disclosed (8-K item 3.02)

ESLAW offering-related filings from SEC EDGAR, newest first (capped at 40). Each links to the original document.

Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.

Is a shelf active now? →Do they need money? →Red flags →Full ESLAW workspace →

ESLAW offering FAQ

When did ESLAW last execute an offering?

Per SEC filings, Estrella Immunopharma, Inc.'s most recent priced offering document is a 424B5 filed 2026-01-06. Note a 424B takedown can price shares or notes (debt) — the linked document says which.

When did ESLAW last announce or register an offering?

The most recent registration is a S-1/A filed 2026-01-22. A registration is capacity to sell shares — not a sale.

Does an offering always mean dilution?

Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.